A major obstacle to developing an effective HIV-1 vaccine is in determining how to elicit broadly neutralizing antibodies (NtAb). It has been shown in passive immunization studies in animal model systems that neutralizing antibodies can block infection by HIV-1 (or SHIV). Thus, findings ways to elicit potent NtAb responses that can block circulating HIV-1 strains is a high priority for the vaccine field. However, the repertoire of broadly neutralizing antibodies under study, particularly antibodies from individuals infected with the more prevalent subtypes worldwide (A, C, D), is very limited. In addition, these antibodies are not particularly effective at neutralizing the envelope protein of transmitted strains of HIV-1, which have distinct characteristics compared to those present at later stages in infection. Here, we propose to use natural history studies in HIV-1 infected humans to identify examples of individuals who develop broad and potent neutralizing antibodies to their HIV-1 infection. We developed a longitudinal cohort study of women infected with subtypes A, C and D in Mombasa, Kenya in 1993. Longitudinal samples have been collected and stored from this cohort during that time, and we plan to continue to monitor these women. We propose to use the power of this unique longitudinal study to address the hypothesis that there are individuals who have broadly neutralizing antibodies capable of blocking transmitted strains. Here we propose to identify such individuals, and to isolate the corresponding antibodies.
The Aims of this grant are: 1) To identify individuals from a group of ~120 women with >5 years of follow-up after their infection who have broad NtAb responses, and specifically have broad and potent NtAbs against recently transmitted strains of subtypes A, C and D. 2) To develop a competition assay that will distinguish cases where breadth is due to one or a few antibodies with broad specificity versus those where the breadth simply reflects a compilation of many antibodies of narrow specificity. 3) To isolate antibodies from subject(s) with broad and potent antibody responses that were elicited in response to infection by the most prevalent subtypes of HIV-1. We believe the approach proposed here, which focuses on a unique longitudinal cohort of HIV-1 infected subjects has the potential for high payoff, as it could ultimately provide insights into the types of antibodies that are needed for effective protection by vaccination.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD058304-03
Application #
7635875
Study Section
HIV/AIDS Vaccines Study Section (VACC)
Program Officer
Ryan, Kevin W
Project Start
2007-09-30
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
3
Fiscal Year
2009
Total Cost
$449,406
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Provine, Nicholas M; Cortez, Valerie; Chohan, Vrasha et al. (2012) The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant. Virology 427:25-33
Goo, Leslie; Jalalian-Lechak, Zahra; Richardson, Barbra A et al. (2012) A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection. J Virol 86:10857-61
Pissani, Franco; Malherbe, Delphine C; Robins, Harlan et al. (2012) Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine 30:5519-26
Cortez, Valerie; Odem-Davis, Katherine; McClelland, R Scott et al. (2012) HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response. PLoS Pathog 8:e1002611
Lovelace, Erica; Xu, Hengyu; Blish, Catherine A et al. (2011) The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization. Virology 421:235-44
Humes, Daryl; Overbaugh, Julie (2011) Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells. J Virol 85:4409-20
Bosch, Katherine A; Rainwater, Stephanie; Jaoko, Walter et al. (2010) Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. Virology 398:115-24
Blish, Catherine A; Sather, D Noah; Sellhorn, George et al. (2010) Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J Virol 84:2573-84
Piantadosi, Anne; Panteleeff, Dana; Blish, Catherine A et al. (2009) Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 83:10269-74
Blish, Catherine A; Jalalian-Lechak, Zahra; Rainwater, Stephanie et al. (2009) Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol 83:7783-8